Navigation Links
Using fish to illuminate the architecture of inherited disease
Date:5/24/2010

Durham, N.C. A research team led by scientists from the Duke University Medical Center has developed a way to simultaneously look at the effects of 125 mutations occurring on 14 different genes. They used zebrafish as a model to analyze the function of every known mutation in an inherited syndrome called BBS, Bardet-Biedl Syndrome.

Being able to analyze the functions and interactions of all mutations in a complex inherited disease could have implications for a broad range of disorders. The study found that, while mutations at one of at least 14 genes are responsible for the disorder, mutations elsewhere in the genome may modify the severity and diversity of the symptoms.

"The human genome project and new technologies can help us identify mutations in patients' genomes, but the challenge is how to interpret such variation and how to use it to improve the ability to predict what this means with respect to a patient's clinical presentation," said senior author Nicholas Katsanis, Ph.D., Jean and George Brumley Jr., M.D., Professor of Developmental Biology, Professor of Pediatrics and Cell Biology, and Director of the Duke Center for Human Disease Modeling. "Our work demonstrates that it is possible to develop functional bioassays using a vertebrate model that predicts whether a mutation has a role in a complex disease, like Bardet-Biedl syndrome, which we studied."

The study was published online during the week of May 24 in the Proceedings of the National Academy of Sciences.

BBS is an interesting disease to use as a study model because it involves a number of different traits that are highly variable among patients, said Katsanis, whose endowed professorship is in the Neonatal-Perinatal Research Institute at Duke. People with BBS may have retinopathy, obesity, mental retardation, more than the usual number of fingers or toes, and other distinct traits. BBS has become something of a workhorse for understanding variab
'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UCLA engineer gets $4 million from Department of Energy to convert CO2 to liquid fuel using electricity
2. Using remote sensing to track invasive trees
3. Using a pests chemical signals to control it
4. New plastic-like materials may say shhhh to hush disease-causing microbes
5. Project for sailing vessels to maneuver in ports using electric energy from wind
6. K-State professor using NSF award to study the impact of nitrogen deposition on global change
7. Scientists create artificial human skin with biomechanical properties using tissue engineering
8. Beetles stand out using Avatar tech
9. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. IU researchers target vascular disease linked to cancer-causing gene mutation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Mayo Clinic-led researchers is first to devise a system ... killer that hunts down and destroys cancer cells -- ... an advanced electronic article of Nature Biotechnology. , The ... cells, and then redirected the virus to attack diseased, ...
... prenatal care, new research suggests that early infection may ... on the immune system. Researchers at the University of ... a one-time infection as newborns didn't learn as well ... after their immunity was challenged. The research is in ...
... that the antibiotic minocycline might help alleviate HIV's negative ... that can develop even though antiretroviral therapy controls the ... with simian immunodeficiency virus (SIV), a very close relative ... to brain cells, less brain inflammation, and less virus ...
Cached Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... ... camera during an operation he performed for his Discovery Channel television special: Silent Stalker: ... ... Show used VizVOCUS,s popular "plug and play" medical camera during an ...
... England , May 25, 2010 Executives from Heptares,Therapeutics (Welwyn ... of the agreement under which O2h provides multi-FTE -synthetic,chemistry services to support ... , ... said, "We are happy to have signed,this new contract with O2h; they ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
Cached Biology Technology:VizVOCUS's Digital Camera Used by Dr. Mehmet Oz on Discovery Channel Special 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4
Request Info...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: